Remoxipride
From Wikipedia, the free encyclopedia
Remoxipride is a substituted benzamide which was a promising antipsychotic during clinical trials in the 1990's, but was removed due to possible side effects.
[edit] Clinical Trials
Remoxipride is a selective D2 antagonist, with a relatively low effective dosage and low incidence of side effects relative to haloperidol. However, after its introduction in Europe, its use was correlated with incidence of aplastic anemia in as many as 1 in 10,000 cases, and it was taken off the market until its relationship to this possible side effect could be studied.
[edit] External links
 |
This chemistry article is a stub. You can help Wikipedia by expanding it. |
